Hsiao-jen Y. Chung
Beitou, TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
Reply to "Salvage radiotherapy for recurrent prostate cancer diagnosed by prostate-specific membrane antigen positron emission tomography imaging".
Journal: Journal of the Chinese Medical Association : JCMA
Published: January 30, 2026
Salvage radiotherapy with prostate-specific membrane antigen-directed focal boost: A precision approach for recurrent prostate cancer.
Journal: Journal of the Chinese Medical Association : JCMA
Published: September 25, 2025
Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: A single-center real-world study.
Journal: Urologic oncology
Published: April 29, 2025
Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.
Journal: Journal of the Chinese Medical Association : JCMA
Published: April 18, 2025
Equation Predicts Renal Function after Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma.
Equation Predicts Renal Function after Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma.
Journal: International braz j urol : official journal of the Brazilian Society of Urology
Published: March 08, 2025
Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis.
Journal: World journal of urology
Published: January 14, 2025
A prospective study using questionnaires and urodynamic assessments to evaluate bladder function and continence changes after robotic assisted radical prostatectomy.
Journal: Scientific reports
Published: December 09, 2024
Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: November 28, 2023
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Journal: Japanese journal of clinical oncology
Published: November 08, 2023
Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.
Journal: Journal of the Chinese Medical Association : JCMA
Published: June 14, 2023
Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.
Journal: Journal of translational medicine
Published: April 27, 2023
Last Updated: 09/26/2026